🇺🇸 FDA
Pipeline program

osimertinib

D5084C00007

Phase 2 small_molecule active

Quick answer

osimertinib for Carcinoma is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials